https://scholars.lib.ntu.edu.tw/handle/123456789/597547
標題: | Next frontiers in systemic therapy for soft tissue sarcoma | 作者: | Yen C.-C. WEI-WU CHEN |
關鍵字: | Immunotherapy; Molecular targeted therapy; Precision medicine; Soft tissue sarcoma (STS) | 公開日期: | 2018 | 出版社: | AME Publishing Company | 卷: | 7 | 期: | 4 | 來源出版物: | Chinese Clinical Oncology | 摘要: | Soft tissue sarcoma (STS) is a heterogeneous disease with more than 50 subtypes. Once the disease reached locally advanced or metastatic status, the standard treatment remains to be chemotherapy. Current understanding of the underlying molecular and genomic mechanisms of different histology subtypes have led to encouraging development of new drugs in treating STS. Besides molecular targeted therapy, immunotherapy have also shown promising advancement in solid tumor treatments. This review will be in two parts. The first part will focus on the molecular targeted agents aiming at molecular or genetic alterations that are more specific in STS, including antiangiogenic molecules, plate-derived growth factor receptor alpha (PDGFRA) monoclonal antibody, colony-stimulating factor-1 receptor (CSF-1R), selective inhibitors of nuclear export (SINE), cyclin-dependent kinase 4/6 (CDK 4/6), mdm2, and epigenetic regulators. We also discussed in depth about how current precision medicine influences the treatment paradigm in STS. In the second part, we focus on the landscape of immunotherapy in STS including immune checkpoint inhibitors (ICIs) and the combinations of immunotherapies or with other molecules that could modulate the tumor microenvironment. These included the program cell death-1 receptor and its ligand (PD-1/PD-L1), cytotoxic T lymphocyte associated protein-4 (CTLA-4) and the combination with anti-angiogenic agents that could facilitate the trafficking of T cells. Strategies targeting the tumor-associated antigen NY-ESO-1, which is commonly observed in synovial sarcoma and myxoid round cell liposarcoma, via viral vaccines and adoptive T cells will also be discussed. These new frontiers of treatment that are developed with better insights into sarcoma and immune biology hopefully will change the treatment paradigm of advanced STS in the future. ? Chinese Clinical Oncology. |
URI: | https://www.scopus.com/inward/record.uri?eid=2-s2.0-85052589371&doi=10.21037%2fcco.2018.08.04&partnerID=40&md5=844e70dd6f961ea7e8c96c217bebb264 https://scholars.lib.ntu.edu.tw/handle/123456789/597547 |
ISSN: | 2304-3865 | DOI: | 10.21037/cco.2018.08.04 | SDG/關鍵字: | angiogenesis inhibitor; cancer vaccine; colony stimulating factor 1 receptor; colony stimulating factor 1 receptor inhibitor; cyclin dependent kinase 4; cyclin dependent kinase 6; cyclin dependent kinase inhibitor; cytotoxic T lymphocyte antigen 4; immune checkpoint inhibitor; immunological antineoplastic agent; monoclonal antibody; platelet derived growth factor alpha receptor; programmed death 1 ligand; programmed death 1 receptor; protein inhibitor; protein MDM2; selective inhibitor of nuclear export; unclassified drug; virus vaccine; antiangiogenic therapy; cancer immunotherapy; human; liposarcoma; molecularly targeted therapy; personalized medicine; protein expression; Review; soft tissue sarcoma; synovial sarcoma; systemic therapy; T lymphocyte; treatment response; tumor microenvironment; immunotherapy; pathology; procedures; sarcoma; Humans; Immunotherapy; Molecular Targeted Therapy; Precision Medicine; Sarcoma |
顯示於: | 醫學院附設醫院 (臺大醫院) |
在 IR 系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。